Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natpara in Japanese patients with chronic hypoparathyroidism
NCT03878953Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of parathyroid hormone 1-84 in hypoparathyroidism, sponsored by Takeda. Primary endpoints: Number of Responders at 26 weeks and Treatment-Emergent Adverse Events at 30 weeks. Planned start Aug 2022; status: withdrawn.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT03878953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878953.